Trandolapril→see ACE inhibitors
Tranexamic acid→seeTABLE 5p. 847 (thromboembolism)
Tranylcypromine→see monoamine-oxidase A and B inhibitors,
irreversible
Trastuzumab→see monoclonal antibodies
Trastuzumab emtansine→see monoclonal antibodies
Trazodone→seeTABLE 13p. 850 (serotonin syndrome),TABLE 11p. 849
(CNS depressant effects)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure totrazodone.oTheoretical
▶Antiepileptics(carbamazepine)decrease the concentration of
trazodone. Adjust dose.oAnecdotal
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure totrazodone.o
Theoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to moderately increase the exposure totrazodone.
Avoid or adjust dose.oStudy
▶Aprepitantis predicted to increase the exposure totrazodone.
oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure totrazodone.oTheoretical
▶Cobicistatis predicted to moderately increase the exposure to
trazodone. Avoid or adjust dose.oStudy
▶Crizotinibis predicted to increase the exposure totrazodone.
oTheoretical
▶HIV-protease inhibitorsare predicted to moderately increase
the exposure totrazodone. Avoid or adjust dose.o
Study
▶Idelalisibis predicted to moderately increase the exposure to
trazodone. Avoid or adjust dose.oStudy
▶Imatinibis predicted to increase the exposure totrazodone.
oTheoretical
▶Macrolides(clarithromycin)are predicted to moderately
increase the exposure totrazodone. Avoid or adjust dose.
oStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure totrazodone.oTheoretical
▶Netupitantis predicted to increase the exposure totrazodone.
oTheoretical
▶Nilotinibis predicted to increase the exposure totrazodone.
oTheoretical
Tree pollen extract
GENERAL INFORMATIONDesensitising vaccines should be
avoided in patients taking beta-blockers (adrenaline might be
ineffective in case of a hypersensitivity reaction) or ACE
inhibitors (risk of severe anaphylactoid reactions).Treosulfan→see alkylating agents
Tretinoin→see retinoids
Triamcinolone→see corticosteroids
Triamterene→see potassium-sparing diuretics
Tricyclic antidepressants→seeTABLE 18p. 851 (hyponatraemia),
TABLE 8p. 848 (hypotension),TABLE 13p. 850 (serotonin syndrome),
TABLE 9p. 849 (QT-interval prolongation),TABLE 10p. 849
(antimuscarinics)
amitriptyline.clomipramine.dosulepin.doxepin.imipramine.
lofepramine.nortriptyline.trimipramine..
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure totricyclic antidepressants. Avoid.r
Theoretical→Also seeTABLE 9p. 849
▶Antiarrhythmics(propafenone)are predicted to increase the
concentration oftricyclic antidepressants.o
Theoretical→Also seeTABLE 10p. 849
▶Antiepileptics(carbamazepine)decrease the exposure to
tricyclic antidepressants. Adjust dose.oStudy→Also see
TABLE 18p. 851
▶Antiepileptics(phenobarbital, primidone)are predicted to
decrease the exposure totricyclic antidepressants.o
Study
▶Tricyclic antidepressants(clomipramine, imipramine)potentially
increase the risk of overheating and dehydration when given
withantiepileptics(zonisamide). Avoid in children.r
Theoretical
▶Bupropionis predicted to increase the exposure totricyclic
antidepressants. Monitor for toxicity and adjust dose.r
Study→Also seeTABLE 13p. 850
▶Cinacalcetis predicted to increase the exposure totricyclic
antidepressants. Monitor for toxicity and adjust dose.r
Study
▶Tricyclic antidepressantsdecrease the antihypertensive effects
ofclonidine. Monitor and adjust dose.oAnecdotal→
Also seeTABLE 8p. 848
▶Cobicistatis predicted to slightly increase the exposure to
tricyclic antidepressants.nStudy
▶Darifenacinis predicted to increase the exposure totricyclic
antidepressants.oTheoretical→Also seeTABLE 10p. 849
▶Eliglustatis predicted to increase the exposure tonortriptyline.
Adjust dose.oTheoretical
▶Tricyclic antidepressantsare predicted to decrease the
antihypertensive effects ofguanethidine.oStudy→Also
seeTABLE 8p. 848
▶H 2 receptor antagonists(cimetidine)increase the exposure to
tricyclic antidepressants.oStudy
▶HIV-protease inhibitors(ritonavir, tipranavir)are predicted to
increase the exposure totricyclic antidepressants.o
Theoretical
▶Tricyclic antidepressantspotentially increase the risk of
neurotoxicity when given withlithium.rAnecdotal→Also
seeTABLE 13p. 850→Also seeTABLE 9p. 849
▶Amitriptylinedecreases the effects ofmetyrapone. Avoid.
oTheoretical
▶Tricyclic antidepressantsare predicted to increase the risk of
severe toxic reaction when given withmoclobemide. Avoid.
rTheoretical→Also seeTABLE 13p. 850
▶Tricyclic antidepressantsare predicted to increase the risk of
severe toxic reaction when given withmonoamine-oxidase A
and B inhibitors, irreversible. Avoid and for 14 days after
stopping the MAOI.rTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 13p. 850
▶Tricyclic antidepressantsare predicted to decrease the effects
ofmoxonidine. Avoid.oTheoretical→Also seeTABLE 8
p. 848
▶Tricyclic antidepressantsare predicted to decrease the efficacy
ofpitolisant.nTheoretical
▶SSRIs(fluoxetine, paroxetine)are predicted to increase the
exposure totricyclic antidepressants. Monitor for toxicity and
adjust dose.rStudy→Also seeTABLE 18p. 851→Also see
TABLE 13p. 850
▶SSRIs(fluvoxamine)markedly increase the exposure to
clomipramine. Adjust dose.rStudy→Also seeTABLE 18
p. 851→Also seeTABLE 13p. 850
▶SSRIs(fluvoxamine)increase the exposure totricyclic
antidepressants(amitriptyline, imipramine). Adjust dose.r
Study→Also seeTABLE 18p. 851→Also seeTABLE 13p. 850
▶Sucralfateis predicted to decrease the absorption oftricyclic
antidepressants.oStudy
▶Tricyclic antidepressantsincrease the effects of
sympathomimetics, vasoconstrictor(adrenaline/epinephrine,
noradrenaline/norepinephrine, phenylephrine). Avoid.r
Study
▶Tricyclic antidepressantsare predicted to decrease the effects
ofsympathomimetics, vasoconstrictor(ephedrine). Avoid.r
Study
▶Terbinafineis predicted to increase the exposure totricyclic
antidepressants. Monitor for toxicity and adjust dose.r
Study
▶Tricyclic antidepressantsincrease the risk of cardiac
arrhythmias and hypotension when given withthiopental.
oStudy→Also seeTABLE 8p. 848
Trientine
▶Trientinepotentially decreases the absorption ofiron (oral).
oTheoretical
▶Trientinepotentially decreases the absorption ofzinc.
oTheoretical
Trifluoperazine→see phenothiazines
Trihexyphenidyl→seeTABLE 10p. 849 (antimuscarinics)
Trimethoprim→seeTABLE 18p. 851 (hyponatraemia),TABLE 2p. 847
(nephrotoxicity),TABLE 16p. 851 (increased serum potassium)BNFC 2018 – 2019 Trandolapril—Trimethoprim 1005
Interactions|Appendix 1A1